2020
DOI: 10.1080/08870446.2020.1830093
|View full text |Cite
|
Sign up to set email alerts
|

Examination of the best cut-off points of PHQ-2 and GAD-2 for detecting depression and anxiety in Italian cardiovascular inpatients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
10
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(11 citation statements)
references
References 44 publications
1
10
0
Order By: Relevance
“…21,37 However, subsequent validation studies have suggested the cutoff score be lowered to ≥2 to achieve an optimal balance of sensitivity and specificity. [38][39][40] Therefore, the clinical interpretations of the PHQ-2 and GAD-2 as screening measures are consistent with that recommended for the general population and is not altered in a chronic pain sample.…”
Section: Discussionsupporting
confidence: 70%
See 1 more Smart Citation
“…21,37 However, subsequent validation studies have suggested the cutoff score be lowered to ≥2 to achieve an optimal balance of sensitivity and specificity. [38][39][40] Therefore, the clinical interpretations of the PHQ-2 and GAD-2 as screening measures are consistent with that recommended for the general population and is not altered in a chronic pain sample.…”
Section: Discussionsupporting
confidence: 70%
“…This suggestion is in contrast to both the original validation study of the PHQ‐2 and a study of individuals with rheumatoid arthritis which recommended a cutoff score of ≥3 on the PHQ‐2 21,37 . However, subsequent validation studies have suggested the cutoff score be lowered to ≥2 to achieve an optimal balance of sensitivity and specificity 38–40 . Therefore, the clinical interpretations of the PHQ‐2 and GAD‐2 as screening measures are consistent with that recommended for the general population and is not altered in a chronic pain sample.…”
Section: Discussionmentioning
confidence: 93%
“…Furthermore, Section C provides rapid screening of anxious and/or depressive symptoms through an ad hoc question on stressful life events and two well-known instruments, GAD-2 (Spitzer et al, 2006;Kroenke et al, 2007;Giuliani et al, 2021) and PHQ-2 (Spitzer et al, 1999;Kroenke et al, 2003;Giuliani et al, 2021). This is a response to the necessity to investigate the etiology of subjective complaints because, at least in some cases, some impairments can be due to reversible causes, such as affective disorders or drug side effects (Jessen et al, 2020;Liew, 2020a;Si et al, 2020).…”
Section: Discussionmentioning
confidence: 99%
“…Specifically, a screening for anxious and depressive symptoms is proposed as they may be misinterpreted as cognitive issues or may worsen the cognitive impairment (van Rijsbergen et al, 2019;Jessen et al, 2020;Liew, 2020a). To screen anxiety and/or depressive symptoms have been chosen the recently Italian validation of GAD-2 (Generalized Anxiety Disorder; Spitzer et al, 2006;Kroenke et al, 2007;Giuliani et al, 2021) and PHQ-2 (Patient Health Questionnaire; Spitzer et al, 1999;Kroenke et al, 2003;Giuliani et al, 2021), as they are the shortened versions of two well-established and very used screening tools for mood disorders in research and clinical practice (Giuliani et al, 2021).…”
Section: Section C-psychological Manifestationsmentioning
confidence: 99%
“…Additional medical data will include depression and anxiety, measured using the 2-item Patient Health Questionnaire (PHQ-2) and the 2-item Generalised Anxiety Disorder (GAD-2), respectively, at baseline, 6 and 12 months. These questionnaires are derived from the PHQ-9 and GAD-7 and in cardiac patients are shown to have similar sensitivity and specificity as these longer and highly validated questionnaires 51…”
Section: Methods and Analysismentioning
confidence: 99%